Zanubrutinib
Bruton'S Tyrosine Kinase (Btk) Inhibitors
Sold as BRUKINSA
- Drug class
- Bruton'S Tyrosine Kinase (Btk) Inhibitors
- Availability
- See label
- Routes
- Oral
- Markets covered
- 3
- Products on record
- 8
Overview
Zanubrutinib is an active pharmaceutical ingredient in the Bruton'S Tyrosine Kinase (Btk) Inhibitors group (L01EL). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 5 | April 16, 2026 |
| EU European Union | EMA | 1 | November 24, 2025 |
| CA Canada | Health Canada | 2 | May 27, 2026 |
GBUnited Kingdom· MHRA
5 products
Uses
BRUKINSA as monotherapy is indicated for the treatment of adult patients with Waldenström’s macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy.
BRUKINSA as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20- based therapy. BRUKINSA as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL).
BRUKINSA as monotherapy is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. BRUKINSA in combination with obinutuzumab is indicated for the treatment of adult patients with refractory or relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies.
EUEuropean Union· EMA
1 product
Uses
BRUKINSA as monotherapy is indicated for the treatment of adult patients with Waldenström’s macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy.
BRUKINSA as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based therapy. BRUKINSA as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL).
BRUKINSA in combination with obinutuzumab is indicated for the treatment of adult patients with refractory or relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies.
How to take
CACanada· Health Canada
2 products
2 products on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [3].
Brands in Canada (1)
Drug interactions
Known interactions involving Zanubrutinib. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 252. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL537890005 · revised April 16, 2026
- [2]European Medicines Agency · EMEA/H/C/004978 · revised November 24, 2025
- [3]Health Canada (DPD) · 02512963 · revised May 27, 2026
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.